Forte Biosciences, Inc. (FBRX) |
| 76.99 0 (0%) 08-27 16:00 |
| Open: | 76.97 |
| High: | 76.99 |
| Low: | 76.97 |
| Volume: | 0 |
| Market Cap: | 1,634(M) |
| PE Ratio: | -16.59 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 90.17 |
| Resistance 1: | 77.20 |
| Pivot price: | 76.90 |
| Support 1: | 76.69 |
| Support 2: | 76.38 |
| 52w High: | 77.2 |
| 52w Low: | 10.11 |
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Financials
| EPS | -4.570 |
| Book Value | 7.520 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -37.8 |
| Return on Equity (ttm) | -62.3 |
Company news
Wed, 26 Aug 2026
Forte Biosciences, Inc.(NasdaqCM: FBRX) dropped from S&P TMI Index - www.marketscreener.com
Tue, 11 Aug 2026
Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences - Yahoo Finance
Tue, 28 Jul 2026
Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears - Yahoo Finance
Tue, 28 Jul 2026
Barclays cuts Forte Biosciences stock rating on acquisition terms - Investing.com
Mon, 27 Jul 2026
argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX) - Seeking Alpha
Mon, 27 Jul 2026
Forte Biosciences to Be Acquired by argenx in $77-Per-Share Tender Offer and Merger - TradingView
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
